Feb 13, 2023 8:00 am EST Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
Jan 25, 2023 4:01 pm EST Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Jan 9, 2023 7:00 am EST Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Dec 28, 2022 8:00 am EST Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Dec 6, 2022 6:00 am EST Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Dec 1, 2022 8:00 am EST Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
Nov 14, 2022 8:00 am EST Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Nov 7, 2022 4:05 pm EST Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
Nov 4, 2022 4:30 pm EDT Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update